BACKGROUND: Ulcerative colitis and Crohn's disease are 2 distinct forms of IBD that can overlap radiologically, endoscopically, and pathologically. This difficulty complicates surgical options. The development of new technologies providing accurate diagnosis of IBD is needed. Raman spectroscopy is a noninvasive method that uses the intrinsic properties of tissue and that tissue's vibrational energy in reaction to light. PURPOSE: We hypothesize that Raman spectroscopy can detect the structural and compositional changes that occur in the tissue during the development of inflammatory bowel disease, and thus may offer increased diagnostic certainty in the differentiation between Crohn's disease and ulcerative colitis. METHODS: Fresh frozen colon tissue biopsies from patients with ulcerative colitis (n = 12) and with Crohn's disease (n = 9) were measured in vitro using a custom-designed Raman fiber-optic probe. For spectra collection, the probe was placed in gentle contact with the mucosa surface for 3 seconds, with excitation power at 150 mW. Five spectra were acquired from each biopsy to increase the signal-to-noise ratio and to ensure repeatability of data collection. Mean spectra were analyzed for peak difference and molecular origin. RESULTS: Significant difference was observed between the spectra from each disease in the spectral regions assigned to nucleic acid, phenylalanine, and lipids. Tissue samples from patients with ulcerative colitis demonstrated higher content of lipid and lower amount of phenylalanine and nucleic acid. These characteristic Raman features could serve as spectral markers that can potentially be applied to distinguish ulcerative colitis and Crohn's disease. CONCLUSIONS: This study presents the only application of Raman spectroscopy in the diagnosis of inflammatory bowel disease. The feasibility of this technique in differentially detecting molecular alterations in ulcerative colitis and Crohn's disease has been demonstrated, indicating the potential to improve diagnostic accuracy of inflammatory bowel disease.
BACKGROUND:Ulcerative colitis and Crohn's disease are 2 distinct forms of IBD that can overlap radiologically, endoscopically, and pathologically. This difficulty complicates surgical options. The development of new technologies providing accurate diagnosis of IBD is needed. Raman spectroscopy is a noninvasive method that uses the intrinsic properties of tissue and that tissue's vibrational energy in reaction to light. PURPOSE: We hypothesize that Raman spectroscopy can detect the structural and compositional changes that occur in the tissue during the development of inflammatory bowel disease, and thus may offer increased diagnostic certainty in the differentiation between Crohn's disease and ulcerative colitis. METHODS: Fresh frozen colon tissue biopsies from patients with ulcerative colitis (n = 12) and with Crohn's disease (n = 9) were measured in vitro using a custom-designed Raman fiber-optic probe. For spectra collection, the probe was placed in gentle contact with the mucosa surface for 3 seconds, with excitation power at 150 mW. Five spectra were acquired from each biopsy to increase the signal-to-noise ratio and to ensure repeatability of data collection. Mean spectra were analyzed for peak difference and molecular origin. RESULTS: Significant difference was observed between the spectra from each disease in the spectral regions assigned to nucleic acid, phenylalanine, and lipids. Tissue samples from patients with ulcerative colitis demonstrated higher content of lipid and lower amount of phenylalanine and nucleic acid. These characteristic Raman features could serve as spectral markers that can potentially be applied to distinguish ulcerative colitis and Crohn's disease. CONCLUSIONS: This study presents the only application of Raman spectroscopy in the diagnosis of inflammatory bowel disease. The feasibility of this technique in differentially detecting molecular alterations in ulcerative colitis and Crohn's disease has been demonstrated, indicating the potential to improve diagnostic accuracy of inflammatory bowel disease.
Authors: Eladio Rodriguez-Diaz; Christopher Atkinson; Lisa I Jepeal; Adam Berg; Christopher S Huang; Sandra R Cerda; Michael J OʼBrien; Irving J Bigio; Francis A Farraye; Satish K Singh Journal: Inflamm Bowel Dis Date: 2014-06 Impact factor: 5.325
Authors: Tomasz Dawiskiba; Stanisław Deja; Agata Mulak; Adam Ząbek; Ewa Jawień; Dorota Pawełka; Mirosław Banasik; Agnieszka Mastalerz-Migas; Waldemar Balcerzak; Krzysztof Kaliszewski; Jan Skóra; Piotr Barć; Krzysztof Korta; Kornel Pormańczuk; Przemyslaw Szyber; Adam Litarski; Piotr Młynarz Journal: World J Gastroenterol Date: 2014-01-07 Impact factor: 5.742
Authors: Isaac J Pence; Dawn B Beaulieu; Sara N Horst; Xiaohong Bi; Alan J Herline; David A Schwartz; Anita Mahadevan-Jansen Journal: Biomed Opt Express Date: 2017-01-04 Impact factor: 3.732
Authors: Gian Eugenio Tontini; Maurizio Vecchi; Luca Pastorelli; Markus F Neurath; Helmut Neumann Journal: World J Gastroenterol Date: 2015-01-07 Impact factor: 5.742
Authors: Riana Gaifulina; Andrew Thomas Maher; Catherine Kendall; James Nelson; Manuel Rodriguez-Justo; Katherine Lau; Geraint Mark Thomas Journal: Int J Exp Pathol Date: 2016-09-01 Impact factor: 1.925
Authors: Maximilian J Waldner; Timo Rath; Sebastian Schürmann; Christian Bojarski; Raja Atreya Journal: Front Immunol Date: 2017-10-11 Impact factor: 7.561